JUN 04, 2020 6:30 AM PDT

Low T Cells Linked To High COVID Risk

WRITTEN BY: Tara Fernandez

German scientists have identified a connection between immune cell counts and the risk of developing severe, potentially life-threatening symptoms of COVID-19. The team, led by professor of virology, Ulf Dittmer, found that people who have low T cell counts at the time of infection have higher odds of developing a severe form of COVID-19. The study was published in the medical journal, The Lancet.

The numbers of a particular subpopulation of T cells, called cytotoxic T cells, in the blood were found to be central to this response. These immune cells protect the body by killing cancerous or virally-infected cells. 

It’s not just the number of T cells that count. The ratio of cytotoxic T cells to another type of immune cell, neutrophils, was also found to be important. T cells and neutrophils serve different but complementary roles in the protective immune response and have strong regulatory effects on each other.

“If there are too many neutrophils in the blood, they tend to suppress the function of T-cells. It can, therefore, be assumed that an elevated number of neutrophils in COVID-19 patients might contribute to a decrease in T cell counts,” explained Dittmer.

Common initial symptoms following coronavirus infection include fever, cough, fatigue, and diarrhea. More severe symptoms typically develop around a week later, in which the conditions of these patients rapidly deteriorate as acute respiratory distress syndrome, or ARDS, sets in. As symptoms progress, COVID-19 has also led to heart, kidney and liver damage and, in the worst cases, death. Being able to identify patients most at risk would allow physicians to initiate intensive interventions earlier and improve clinical outcomes.

 

 

The team’s investigation looked at 40 COVID-19 patients in Wuhan, China. Their studies suggest that a simple blood test for T cell and neutrophil counts should be done to quickly pick out at-risk COVID-19 patients. These patients need to be monitored more closely and perhaps be treated at an earlier stage, said Dittmer.

Patients receiving medications or therapies that can damage T cells, such as chemotherapy, should also be more closely monitored given this finding. 

The team’s finding also has implications for the development of a vaccine against the virus that causes COVID-19, SARS-CoV-2. A vaccine capable of shielding against infection may not only need to trigger the production of antibodies, but also activate T cell responses in order to confer robust protection.

 

Sources: Innovation Origins, The Lancet, The New England Journal of Medicine.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
AUG 12, 2020
Cancer
Comparing Nivolumab and Pembrolizumab in the Treatment of Lung Cancer
AUG 12, 2020
Comparing Nivolumab and Pembrolizumab in the Treatment of Lung Cancer
Since the 1940s, chemotherapy has been a primary treatment option for cancer. The late 20th century brought a new type o ...
SEP 07, 2020
Cell & Molecular Biology
With Nanopores, Small Samples Detect Diseases
SEP 07, 2020
With Nanopores, Small Samples Detect Diseases
If you've ever been through a battery of tests while doctors try to find a diagnosis for an ailment, you know that many ...
SEP 29, 2020
Drug Discovery & Development
Cycling Molecules into Drug Candidates
SEP 29, 2020
Cycling Molecules into Drug Candidates
Statistics show that just 1 in 5,000 drug candidates ever makes it from the lab to the pharmacy. In a process that can t ...
SEP 25, 2020
Clinical & Molecular DX
Ray of Hope: Rare Cancer Biomarker Discovered
SEP 25, 2020
Ray of Hope: Rare Cancer Biomarker Discovered
Biliary tract cancer, or BTC, isn’t as talked about as breast or prostate cancers, probably because its incidence ...
NOV 10, 2020
Clinical & Molecular DX
No More False-Negatives: An Ultrasensitive COVID Test
NOV 10, 2020
No More False-Negatives: An Ultrasensitive COVID Test
A team of researchers has improved upon the current diagnostic methodology for COVID-19, making it significantly more ac ...
DEC 01, 2020
Cardiology
The Benefits of Exercise on Adipokine Levels for Post-Menopausal Women
DEC 01, 2020
The Benefits of Exercise on Adipokine Levels for Post-Menopausal Women
The benefits of a healthy lifestyle don’t just stop when you get older. Being active has been shown to improve pos ...
Loading Comments...